Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alejandro EU, Gregg B, Blandino-Rosano M, Cras-Méneur C, Bernal-Mizrachi E. Natural history of β-cell adaptation and failure in type 2 diabetes. Mol Aspects Med. 2015;42:19–41.

Article  CAS  PubMed  Google Scholar 

International Diabetes Federation. IDF Diabetes Atlas, 10th Ed. Brussels, Belgium : International Diabetes Federation; 2021. https://diabetesatlas.org/ Accessed 10 Jan 2023

Mannucci E, Dicembrini I, Lauria A, Pozzilli P. Is glucose control important for prevention of cardiovascular disease in diabetes? Diabetes Care. 2013;36(Suppl 2):S259–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cernea S, Dobreanu M. Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochem Med (Zagreb). 2013;23(3):266–80.

Article  CAS  PubMed  Google Scholar 

Baxter M, Hudson R, Mahon J, et al. Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit. Diabet Med. 2016;33:1575–81.

Article  CAS  PubMed  Google Scholar 

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.

Article  CAS  PubMed  Google Scholar 

Al-Saleh Y, Sabico S, Al-Furqani A, et al. Sulfonylureas in the current practice of type 2 diabetes management: Are they all the same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas. Diabetes Ther. 2021;12(8):2115–32.

Article  PubMed  PubMed Central  Google Scholar 

Amod A. The place of sulfonylureas in guidelines: why are there differences? Diabetes Ther. 2020;11(Suppl 1):5–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohan V, Khunti K, Chan SP, et al. Management of type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment. Diabetes Ther. 2020;11(1):15–35.

Article  PubMed  Google Scholar 

Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51(Suppl 3):S368–76.

Article  CAS  PubMed  Google Scholar 

Khunti K, Hassanein M, Lee MK, Mohan V, Amod A. Role of gliclazide MR in the management of type 2 diabetes: report of a symposium on real-world evidence and new perspectives. Diabetes Ther. 2020;11(Suppl 2):33–48.

Article  PubMed  PubMed Central  Google Scholar 

Kalra S, Bahendeka S, Sahay R, et al. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus—International Task Force. Indian J Endocrinol Metab. 2018;22(1):132–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh AK, Singh R. Is gliclazide a sulfonylurea with difference? A review in 2016. Expert Rev Clin Pharmacol. 2016;9:839–51.

Article  CAS  PubMed  Google Scholar 

Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complicat. 2003;17:11–5.

Article  Google Scholar 

Drouin P. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study. J Diabetes Complicat. 2000;14(4):185–91.

Article  CAS  Google Scholar 

Drouin P, Standl E, Diamicron MR, Study Group. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabetes Obes Metab. 2004;6(6):414–21.

Article  CAS  PubMed  Google Scholar 

WHO model list of essential medicines - 22nd list, 2021. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02 Accessed 10 Jan 2023

Colagiuri S, Matthews D, Leiter LA, Chan SP, Sesti G, Marre M. The place of gliclazide MR in the evolving type 2 diabetes landscape: a comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Res Clin Pract. 2018;143:1–14.

Article  CAS  PubMed  Google Scholar 

Kalra S, Unnikrishnan AG, Bantwal G, Das S, Polavarapu NK, Gaurav K. The position of gliclazide in the evolving landscapes and disease continuum of T2DM: a collaborative Delphi survey-based consensus from India. Diabetes Ther. 2021;12(3):679–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9–16.

Article  CAS  PubMed  Google Scholar 

American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl 1):S90–102.

Article  Google Scholar 

Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221–8.

Article  PubMed  Google Scholar 

National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NICE Guideline 28). 2015 (last updated 2020). www.nice.org.uk/guidance/NG28. Accessed 10 Jan 2023

Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boye KS, Thieu VT, Lage MJ, Miller H, Paczkowski R. The association between sustained hba1c control and long-term complications among individuals with type 2 diabetes: a retrospective study. Adv Ther. 2022;39(5):2208–21.

Article  PubMed  PubMed Central  Google Scholar 

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.

Article  Google Scholar 

Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.

Article  CAS  PubMed  Google Scholar 

Patel A, MacMahon S, ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.

Article  CAS  PubMed  Google Scholar 

Zoungas S, Chalmers J, Neal B, et al. ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392–406.

Article  PubMed  Google Scholar 

Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.

Article  CAS  PubMed  Google Scholar 

Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298–307.

Article  PubMed  PubMed Central  Google Scholar 

Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44.

Article  PubMed